Shibo Jiang Selected Research

Vaccines

2/2024	Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
12/2023	An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen.
12/2023	Application of "B+1" heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines.
11/2023	Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
1/2023	SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
4/2022	Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
1/2022	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
1/2022	A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
1/2022	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
1/2022	Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shibo Jiang Research Topics

Disease

183	Infections 04/2024 - 09/2002
38	COVID-19 04/2024 - 01/2020
32	Virus Diseases (Viral Diseases) 03/2024 - 03/2005
26	Human Influenza (Influenza) 03/2024 - 08/2006
21	Severe Acute Respiratory Syndrome 04/2022 - 09/2004
20	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 01/2002
10	HIV Infections (HIV Infection) 01/2020 - 01/2002
8	Influenza in Birds (Avian Flu) 06/2023 - 07/2010
8	Zika Virus Infection 01/2022 - 01/2017
8	Coronavirus Infections 01/2022 - 01/2015
6	Neoplasms (Cancer) 11/2022 - 02/2008
5	Communicable Diseases (Infectious Diseases) 02/2024 - 01/2017
5	Papillomavirus Infections 01/2023 - 06/2013
5	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2022 - 08/2015
4	Bites and Stings (Sting) 01/2023 - 01/2020
4	Lung Injury 11/2020 - 01/2014
3	Breakthrough Infections 11/2023 - 01/2022
3	Respiratory Syncytial Virus Infections 01/2021 - 01/2013
3	Inflammation (Inflammations) 01/2020 - 06/2012
3	Acute Lung Injury 04/2018 - 10/2011
2	Pneumonia (Pneumonitis) 01/2022 - 11/2020
2	Immune System Diseases (Immune Disorders) 11/2020 - 01/2017
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 05/2020 - 03/2016
2	Poisoning 01/2018 - 10/2011
2	Hemorrhagic Fever with Renal Syndrome (HFRS) 09/2008 - 11/2002

Drug/Important Bio-Agent (IBA)

69	VaccinesIBA 02/2024 - 09/2004
68	Proteins (Proteins, Gene)FDA Link 04/2024 - 09/2004
52	Antiviral Agents (Antivirals)IBA 04/2024 - 09/2002
47	Peptides (Polypeptides)IBA 03/2024 - 01/2002
28	Neutralizing AntibodiesIBA 12/2023 - 09/2006
19	AntibodiesIBA 03/2024 - 11/2004
17	Monoclonal AntibodiesIBA 01/2022 - 11/2002
13	Anti-Infective Agents (Microbicides)IBA 01/2017 - 04/2002
11	Subunit VaccinesIBA 01/2022 - 01/2008
10	Immunoglobulin G (IgG)IBA 03/2024 - 12/2006
10	Glycoproteins (Glycoprotein)IBA 01/2022 - 04/2002
10	EpitopesIBA 10/2019 - 11/2002
9	Recombinant ProteinsIBA 04/2024 - 09/2008
9	Amyloid (Amyloid Fibrils)IBA 03/2024 - 11/2012
9	HIV Fusion InhibitorsIBA 01/2022 - 01/2002
8	Enfuvirtide (Fuzeon)FDA Link 08/2015 - 01/2004
7	Immune Sera (Antisera)IBA 11/2020 - 09/2004
6	Broadly Neutralizing AntibodiesIBA 01/2023 - 01/2017
5	Influenza Vaccines (Influenza Vaccine)FDA Link 06/2023 - 07/2010
5	Human Serum Albumin FDA LinkGeneric 03/2022 - 03/2013
5	Anti-HIV Agents (AIDS Drugs)IBA 01/2022 - 01/2002
5	3-hydroxyphthalic anhydrideIBA 01/2022 - 04/2011
5	Hemagglutinins (Hemagglutinin)IBA 07/2020 - 06/2013
5	Reverse Transcriptase InhibitorsIBA 07/2018 - 01/2004
5	Protease Inhibitors (Protease Inhibitor)IBA 12/2012 - 01/2002
4	Amino Acids FDA Link 04/2024 - 09/2006
4	Polysaccharides (Glycans)IBA 04/2024 - 06/2005
4	Therapeutic UsesIBA 01/2023 - 10/2019
4	Nelfinavir (Viracept)FDA Link 11/2022 - 08/2015
4	Peptide Hydrolases (Proteases)FDA Link 04/2022 - 09/2005
4	CytokinesIBA 11/2020 - 06/2012
4	Complement System Proteins (Complement)IBA 04/2018 - 10/2011
3	Inactivated VaccinesIBA 11/2023 - 09/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 10/2023 - 08/2005
3	HIV Protease InhibitorsIBA 11/2022 - 08/2015
3	LipopeptidesIBA 04/2022 - 04/2020
3	CholesterolIBA 01/2022 - 06/2014
3	COVID-19 VaccinesIBA 01/2022 - 01/2021
3	Interleukin-6 (Interleukin 6)IBA 11/2020 - 06/2012
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 10/2020 - 08/2002
3	InterferonsIBA 01/2020 - 01/2014
3	NucleosidesIBA 07/2018 - 12/2010
3	Zidovudine (Retrovir)FDA LinkGeneric 07/2018 - 05/2005
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2017 - 01/2013
3	AntigensIBA 12/2016 - 09/2008
3	OvalbuminIBA 03/2013 - 09/2008
3	CD4 Antigens (CD4 Antigen)IBA 01/2013 - 09/2005
3	sifuvirtideIBA 02/2011 - 04/2008
2	EnzymesIBA 03/2024 - 07/2008
2	MF59 oil emulsionIBA 03/2024 - 03/2016
2	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 12/2022
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2022 - 01/2020
2	GossypolIBA 01/2022 - 11/2019
2	Lactoglobulins (beta-Lactoglobulin)FDA Link 01/2022 - 06/2013
2	Drug CombinationsIBA 01/2021 - 04/2019
2	Metformin (Glucophage)FDA LinkGeneric 04/2019 - 01/2017
2	Peptide FragmentsIBA 01/2018 - 10/2017
2	ParaquatIBA 01/2018 - 10/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2018 - 01/2013
2	avian influenza A virus hemagglutininIBA 10/2017 - 10/2013
2	4Dm2mIBA 06/2017 - 05/2016
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 06/2012
2	ADS J1IBA 09/2015 - 05/2014
2	Palivizumab FDA Link 02/2015 - 01/2013
2	Maleic Anhydrides (Maleic Anhydride)IBA 02/2015 - 03/2013
2	piperidineIBA 05/2012 - 06/2011
2	Recombinant Fusion ProteinsIBA 01/2011 - 10/2010
2	IntegrasesIBA 09/2010 - 09/2005
2	Human immunodeficiency virus 1 reverse transcriptaseIBA 09/2010 - 05/2005
2	SARS-CoV spike glycoproteinIBA 01/2008 - 03/2004

Therapy/Procedure

51	Therapeutics 04/2023 - 04/2006
6	Highly Active Antiretroviral Therapy (HAART) 01/2022 - 05/2011
3	Salvage Therapy 07/2018 - 09/2014
2	Immunotherapy 01/2022 - 11/2002
2	Intranasal Administration 01/2022 - 02/2015